Remicade
Market Access/ News/ News/ Top stories
J&J faces FTC probe on Remicade biosimilar defence
Phil Taylor
biosimilar, Inflectra, Johnson & Johnson, Pfizer, Remicade
0 Comment
Stelara gains US approval for Crohn’s disease
Andrew McConaghie
Crohn's, inflammatory, Janssen, Remicade
0 Comment
New use for patients who fail anti-TNF drugs
No US Remicade biosimilar until at least October
Richard Staines
biosimilar, J&J, Remicade, sales
0 Comment
Pfizer must wait until 180 day period ends, court fight ongoing.
Biosimilar switching not suitable for all patients
Richard Staines
biosimilars, gastrointestinal, Remicade, Rheumatoid arthritis
0 Comment
Antibodies against originator will also target biosimilar.